ARK Venture Fund invests in Cellares’ Series D round
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cabaletta Bio Inc (CABA)
Cabaletta Bio Inc stock price live, this page displays NASDAQ CABA stock exchange data. View the CABA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cabaletta Bio Inc real time stock price chart below.
What Is the Cabaletta Bio Inc Stock Price Today?
The Cabaletta Bio Inc stock price today is 3.190.
What Is the Stock Symbol for Cabaletta Bio Inc?
The stock symbol for Cabaletta Bio Inc is "CABA."
What Stock Exchange Does Cabaletta Bio Inc Trade On?
Cabaletta Bio Inc is listed and trades on the NASDAQ stock exchange.
Is Cabaletta Bio Inc a Good Stock to Buy?
Determining whether Cabaletta Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CABA quote. (ISIN: US12674W1099)
What Is the Cabaletta Bio Inc Stock Price Today?
The Cabaletta Bio Inc stock price today is 3.190.
What Is the Stock Symbol for Cabaletta Bio Inc?
The stock symbol for Cabaletta Bio Inc is "CABA."
What Stock Exchange Does Cabaletta Bio Inc Trade On?
Cabaletta Bio Inc is listed and trades on the NASDAQ stock exchange.
Is Cabaletta Bio Inc a Good Stock to Buy?
Determining whether Cabaletta Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CABA quote. (ISIN: US12674W1099)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.080
3.280
52 wk Range
1.260
4.230
CABA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.0803.280
52 wk Range
1.2604.230
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CABA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
13.375
Upside
+319.28%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 13G Cabaletta Bio For: 5 June
- Investing.com
- Form 13G CABALETTA BIO INC For: 4 June
- Investing.com
- ARK Venture Fund invests in Cellares’ Series D round
- Investing.com
- Form 13G Cabaletta Bio For: 5 June
- Investing.com
- Form 13G CABALETTA BIO INC For: 4 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.375
(+319.28% Upside)
Cabaletta Bio Inc SWOT Analysis
CAR-T Trailblaze | Cabaletta Bio leads in developing CAR-T therapies for autoimmune diseases, targeting conditions like lupus and myositis with promising clinical results |
Market Disconnect | Explore the intriguing gap between positive clinical reception and market skepticism, presenting a unique investment opportunity in the biotech secto |
Strategic Positioning | Delve into Cabaletta's first-mover advantage in CD19 auto-CAR-T therapy and its potential to reshape treatment paradigms for autoimmune disorders |
Future Prospects | Analyst targets range from $6 to $35, reflecting diverse views on Cabaletta's potential to capitalize on its innovative therapies and market position |
Earnings
Latest Release
May 14, 2026
EPS / Forecast
-0.39 / -0.39
Revenue / Forecast
-- / --
Compare CABA to Peers and Sector
Metrics to compare | CABA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCABAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.0x | −4.3x | −0.4x | |
PEG Ratio | −0.11 | −0.02 | 0.00 | |
Price/Book | 5.0x | 2.6x | 2.6x | |
Price / LTM Sales | - | 7.6x | 3.0x | |
Upside (Analyst Target) | 323.2% | 109.0% | 50.7% | |
Fair Value Upside | Unlock | 16.1% | 6.5% | Unlock |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cabaletta Bio (CABA) Stock Price Today?
The Cabaletta Bio stock price today is 3.190 USD.
What Stock Exchange Does Cabaletta Bio Trade On?
Cabaletta Bio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cabaletta Bio?
The stock symbol for Cabaletta Bio is "CABA."
What Is the Cabaletta Bio Market Cap?
As of today, Cabaletta Bio market cap is 520.140M USD.
What Is Cabaletta Bio's Earnings Per Share (TTM)?
The Cabaletta Bio EPS (TTM) is -1.842.
When Is the Next Cabaletta Bio Earnings Date?
Cabaletta Bio will release its next earnings report on Aug 06, 2026.
From a Technical Analysis Perspective, Is CABA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Cabaletta Bio Stock Split?
Cabaletta Bio has split 0 times.
How Many Employees Does Cabaletta Bio Have?
Cabaletta Bio has 157 employees.
What is the current trading status of Cabaletta Bio (CABA)?
As of Jul 03, 2026, Cabaletta Bio (CABA) is trading at a price of 3.190 USD, with a previous close of 2.990 USD. The stock has fluctuated within a day range of 3.080 USD to 3.280 USD, while its 52-week range spans from 1.260 USD to 4.230 USD.
What Is Cabaletta Bio (CABA) Price Target According to Analysts?
The average 12-month price target for Cabaletta Bio is 13.375 USD, with a high estimate of 30 USD and a low estimate of 4 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +319.28% Upside potential.
What Is the CABA After Hours Price?
CABA's last after hours stock price is 3.181 USD, the stock has decreased by -0.009, or -0.290%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.